McCormick, Conagra, Recon, Yiren and RedHill Report Earnings in Choppy Market Week

Stock Preachers·1 Oct 2026·

·Read original

2▲1 ▼1Impact / 5

Earnings Industry Food Products

CAG ▼

MKC ▲

Summary · why it matters

McCormick & Company reported third quarter net sales up 17.4%, including a 0.9% favorable currency impact, with organic sales growth of 1.9%, adjusted operating income of $359 million versus $294 million a year earlier, and adjusted earnings per share of $0.86 versus $0.85, while reaffirming its fiscal 2026 outlook and citing progress on integration planning for its proposed combination with Unilever Foods. Conagra Brands reported first quarter fiscal 2027 net sales down 1.4%, with organic net sales down 1.1%, reported diluted earnings per share up 5.9% to $0.36 and adjusted earnings per share up 5.1% to $0.41, and reaffirmed fiscal 2027 guidance of organic net sales change between negative 3% and negative 1%, adjusted operating margin of 10.0% to 10.5%, and adjusted earnings per share between $1.40 and $1.50. Recon Technology reported fiscal year 2026 total revenue of RMB109.9 million, or $16.2 million, up 65.8% from RMB66.3 million, with gross margin improving to 33.2% from 23.0% and net loss narrowing to RMB31.6 million, or $4.7 million, from RMB43.7 million, or $6.4 million, and also began operations at its waste plastic chemical recycling plant in Weifang, Shandong Province. Yiren Digital reported second quarter 2026 total loans facilitated of RMB6.3 billion, down 29% from the first quarter and down 69% year over year, with repeat borrowers at 82% of total loans facilitated, insurance clients up 281% year over year and new policies up 177% year over year, and a new share repurchase program of up to $20.0 million authorized on July 2, 2026. RedHill Biopharma acquired exclusive global and U.S. commercialization rights to Rebyota and Clenpiq for a $12 million upfront cash payment funded by $18 million received upfront from its Talicia divestment, with the two GI brands generating approximately $37.5 million in 2025 net sales under Ferring Pharmaceuticals, and also divested its 70% stake in Talicia for $18 million upfront plus up to $35 million in potential worldwide net sales milestone payments.

Conagra Brands, Inc. ▼

McCormick & Company Incorporated ▲